Evidence map›Paper›PMID 35056725›Full record

ArticleMolecules (Basel, Switzerland)2022

Synthesis and Biological Activity of 3-(Heteroaryl)quinolin-2(1

Enrique L Larghi, Alexandre Bruneau, Félix Sauvage, Mouad Alami, Juliette Vergnaud-Gauduchon, Samir Messaoudi

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Domino Aldol-SMolecules (Basel, Switzerland) · 2023
    Article
  3. Review
  4. Autoxidation of 4-Hydrazinylquinolin-2(1Molecules (Basel, Switzerland) · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Enrique L LarghiCNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France.ORCID 0000-0002-9791-4831
Alexandre BruneauInstituto de Química Rosario (IQUIR) CONICET/UNR, FBioyF, Rosario S2002LRK, Argentina.
Félix SauvageCNRS, Institut Galien-Paris Saclay, Université Paris-Saclay, 92296 Châtenay-Malabry, France.
Mouad AlamiCNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France.ORCID 0000-0003-4601-462X
Juliette Vergnaud-GauduchonCNRS, Institut Galien-Paris Saclay, Université Paris-Saclay, 92296 Châtenay-Malabry, France.
Samir MessaoudiCNRS, BioCIS, Université Paris-Saclay, 92290 Châtenay-Malabry, France.ORCID 0000-0002-4994-9001

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the context of our SAR study concerning 6BrCaQ analogues as C-terminal Hsp90 inhibitors, we designed and synthesized a novel series of 3-(heteroaryl)quinolin-2(1

Indexed as

Antineoplastic AgentsHSP90 Heat-Shock ProteinsProtein FoldingCell Line, TumorHumansMolecular StructureQuinolonesStructure-Activity RelationshipAntineoplastic AgentsHSP90 Heat-Shock ProteinsQuinolones3-(heteroaryl)quinolin-2(1H)-ones6BrCaQcytotoxicityHsp90purines

Identifiers

PMID35056725
PMCPMC8778022

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.